Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stock Report

Market Cap: US$597.7m

Aclaris Therapeutics Management

Management criteria checks 1/4

Aclaris Therapeutics' CEO is Neal Walker, appointed in Jul 2012, has a tenure of 13.75 years. total yearly compensation is $3.38M, comprised of 18.2% salary and 81.8% bonuses, including company stock and options. directly owns 1.11% of the company’s shares, worth $6.64M. The average tenure of the management team and the board of directors is 1.4 years and 11.6 years respectively.

Key information

Neal Walker

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage18.22%
CEO tenure13.8yrs
CEO ownership1.1%
Management average tenure1.4yrs
Board average tenure11.6yrs

Recent management updates

Recent updates

There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump

Feb 03
There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 25% Share Price Surge Not Quite Adding Up

Dec 19
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 25% Share Price Surge Not Quite Adding Up

Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 31%

Oct 31
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 31%

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Deliver On Growth Plans?

Sep 04
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Deliver On Growth Plans?

Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates

Aug 10
Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates

Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26%

Jun 12
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26%

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?

May 21
Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?

Some Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shareholders Look For Exit As Shares Take 31% Pounding

Apr 23
Some Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shareholders Look For Exit As Shares Take 31% Pounding

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Mar 07
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule

Feb 11

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 12
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

Aug 08
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

May 03
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

CEO Compensation Analysis

How has Neal Walker's remuneration changed compared to Aclaris Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$3mUS$615k

-US$65m

Sep 30 2025n/an/a

-US$142m

Jun 30 2025n/an/a

-US$135m

Mar 31 2025n/an/a

-US$130m

Dec 31 2024US$1mUS$477k

-US$132m

Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$59m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$74kn/a

-US$88m

Sep 30 2023n/an/a

-US$115m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$6mUS$590k

-US$87m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$7mUS$567k

-US$91m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$71m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$2mUS$424k

-US$51m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$3mUS$500k

-US$114m

Compensation vs Market: Neal's total compensation ($USD3.38M) is above average for companies of similar size in the US market ($USD2.45M).

Compensation vs Earnings: Neal's compensation has increased whilst the company is unprofitable.

CEO

Neal Walker (55 yo)

13.8yrs
Tenure
US$3,375,591
Compensation

Dr. Neal S. Walker, D.O. & M.D., is Co-Founder of Aclaris Therapeutics, Inc. and serves as Chief Executive Officer & Chairman since February 2025. He joined firm in July 2012. At Aclaris Therapeutics, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder13.8yrsUS$3.38m1.11%
$ 6.6m
Hugh M. Davis
President1.4yrsno data0.033%
$ 195.3k
Kevin Balthaser
Chief Financial Officer3.3yrsUS$1.49m0.13%
$ 806.0k
James Loerop
Chief Business Officer4.3yrsUS$1.45m0.14%
$ 826.7k
Roland Kolbeck
Chief Scientific Officerless than a yearno datano data
William Roberts
Senior Vice President of Corporate Communications & Investor Relations1.3yrsno datano data
Matthew Rothman
General Counsel & Corporate Secretary3.8yrsno datano data
Jon Jacobsen
Senior Vice President of Chemistryno datano datano data
Steve Tucker
Executive Vice President of Project Leadership2.3yrsno datano data
Jesse Hall
Chief Medical Officer1yrno datano data
Nina Samra
Senior Vice President of Clinical Operations1.3yrsno datano data
Meghan Dunsmore
Senior Vice President of Finance1.3yrsno datano data
1.4yrs
Average Tenure
56yo
Average Age

Experienced Management: ACRS's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder13.8yrsUS$3.38m1.11%
$ 6.6m
Hugh M. Davis
President1.4yrsno data0.033%
$ 195.3k
Vincent Milano
Independent Director6.3yrsUS$120.49k0.012%
$ 74.5k
Mark Bradshaw
Member of Advisory Boardno datano datano data
James Leyden
Member of Advisory Boardno datano datano data
Klaus Theobald
Member of Advisory Boardno datano datano data
Anand Mehra
Independent Director11.6yrsUS$120.49k0.51%
$ 3.1m
Guy Webster
Member of Advisory Boardno datano datano data
Christopher Molineaux
Lead Independent Director12.3yrsUS$141.99k0.042%
$ 249.2k
Kenneth Beer
Member of Advisory Boardno datano datano data
Leslie Baumann
Member of Advisory Boardno datano datano data
Andrew Ondo
Member of Advisory Boardno datano datano data
11.6yrs
Average Tenure
63yo
Average Age

Experienced Board: ACRS's board of directors are seasoned and experienced ( 11.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/27 01:47
End of Day Share Price 2026/04/27 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aclaris Therapeutics, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prakhar AgrawalCantor Fitzgerald & Co.
Donald EllisCitizens JMP Securities, LLC
Adam VogelCraig-Hallum Capital Group LLC